IRVING, Texas: In one of the most significant consumer-goods mergers of the year, Kimberly-Clark is buying Tylenol maker Kenvue in a cash-and-stock deal valued at US$48.7 billion, bringing some of the world's most recognizable health and household brands under a single corporate roof.

The combined company will control a sprawling lineup of staples, from Kleenex, Huggies, and Cottonelle to Tylenol, Band-Aid, and Listerine, and generate roughly $32 billion in annual revenue. Kimberly-Clark shareholders will own 54 percent of the new company, while Kenvue shareholders will hold 46 percent, pending approval from both sets of investors.

Shares of New Jersey-based Kenvue, which was spun off from Johnson & Johnson just two years ago, jumped 12 percent on November 3 after the announcement. Kimberly-Clark's stock, however, slid 15 percent, as Wall Street digested the scale of the acquisition and the challenges of integrating two massive consumer portfolios.

"Kenvue's brands — Neutrogena, Aveeno, Benadryl, Band-Aid — have decades of loyalty built in," said Keonhee Kim, an analyst at Morningstar. "The deal gives Kimberly-Clark a stronger presence in health and personal care and helps unlock value that Kenvue struggled to realize as a stand-alone company."

Since going public, Kenvue's shares have lost nearly half their value, weighed down by management turnover, activist investor pressure, and stagnant growth. In July, Kenvue's CEO Thibaut Mongon resigned amid a strategic review. Critics have faulted the company for relying too heavily on legacy products rather than innovation.

Kenvue has also been under political scrutiny. Earlier this year, President Donald Trump and Health Secretary Robert F. Kennedy Jr. drew controversy by linking Tylenol's use during pregnancy to autism, claims that medical experts have widely discredited. The Food and Drug Administration only advises doctors to "consider minimizing" acetaminophen use during pregnancy out of caution, but found no proven link to autism.

Kenvue reacted strongly, saying it "strongly disagrees" with the allegations and warning that misinformation could endanger public health.

The merger faces additional hurdles. Analysts such as Filippo Falorni at Citi Research cautioned that the deal's size and timing may be risky given the weak track record of large consumer-goods mergers. In recent years, giants like Kraft Heinz have struggled to achieve promised synergies, with net revenues falling every year since 2020.

Both Kimberly-Clark and Kenvue are contending with rising competition from store brands, which, according to Circana, captured 51 percent of U.S. toilet paper sales and 24 percent of over-the-counter health product sales in 2024. A 100-count bottle of extra-strength Tylenol, for instance, costs $10.97 at Walmart — compared to $1.98 for the retailer's own acetaminophen brand, Equate.

Still, analysts say Kimberly-Clark's strength in essentials and Kenvue's dominance in healthcare could give the combined company resilience. Many of their brands, from Kotex to Neutrogena, operate in categories where consumers are less likely to switch to cheaper alternatives.

Kimberly-Clark CEO Mike Hsu will lead the merged firm, which will keep its headquarters in Irving, Texas, while maintaining significant operations around Kenvue's existing sites. The companies said they expect to achieve $1.9 billion in cost savings within three years of closing, which is expected in the second half of 2026.